Phospholipid-Coated Boronic Oxide Nanoparticles as Boron Agents for Boron Neutron Capture Therapy

Chembiochem. 2023 Aug 1;24(15):e202300186. doi: 10.1002/cbic.202300186. Epub 2023 Jul 4.

Abstract

Minimally invasive boron neutron capture therapy (BNCT) is an elegant approach for cancer treatment. The highly selective and efficient deliverability of boron agents to cancer cells is the key to maximizing the therapeutic benefits of BNCT. In addition, enhancement of the frequencies to achieve boron neutron capture reaction is also significant in improving therapeutic efficacy by providing a highly concentrated boron agent in each boron nanoparticle. As the density of the thermal neutron beam remains low, it is unable to induce high-efficiency cell destruction. Herein, we report phospholipid-coated boronic oxide nanoparticles as agents for BNCT that can provide a highly concentrated boron atom in each nanoparticle. The current system exhibited in vitro BNCT activity seven times higher than that of commercial boron agents. Furthermore, the system could penetrate cancer spheroids deeply, efficiently suppressing thermal neutron irradiation-induced growth.

Keywords: boron neutron capture therapy; drug delivery systems; lipid nanoparticles; organic-inorganic hybrid nanomaterials.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Boron
  • Boron Compounds / therapeutic use
  • Boron Neutron Capture Therapy*
  • Nanoparticles*
  • Oxides
  • Phospholipids

Substances

  • Boron
  • Phospholipids
  • boron oxide
  • Boron Compounds
  • Oxides